Company / R&D Expense
Crinetics Pharmaceuticals, Inc. R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$332.1M
FY2025
5-year range
$84.3M / $332.1M
FY2021-FY2025
Trend
+38.3%
vs FY2024
Sector context
#53 of 210
Health Care
What the data says
Crinetics Pharmaceuticals, Inc.'s r&d expense of $332M is higher than 75% of companies in the Health Care sector (FY2025). R&D Expense has increased for 7 consecutive years, from $5M in FY2018 to $332M in FY2025.
Based on SEC 10-K filings.
$332M in FY2025 with a 5-year CAGR of +68.5%. Top quartile in the Health Care sector.
Improved from $169M to $332M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +36.6%
- 5-Year CAGR
- +68.5%
- 10-Year CAGR
- -
Sector benchmark
Top 25% in Health CareTop 25% of 210This company $332.1M Sector average $644.1M
▼
-48.4% below sector average
Key checks
Key Insights
- Crinetics Pharmaceuticals, Inc.'s r&d expense has grown for 7 consecutive years.
- 5-year CAGR of +68.5%, indicating consistent growth.
- In FY2025, r&d expense increased 38.3% year-over-year.
- Ranks #53 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $332.1M | +38.3% |
| FY2024 | $240.2M | +42.5% |
| FY2023 | $168.5M | +29.4% |
| FY2022 | $130.2M | +54.6% |
| FY2021 | $84.3M | +244.2% |
| FY2020 | $24.5M | +165.1% |
| FY2019 | $9.2M | +81.0% |
| FY2018 | $5.1M | -44.8% |
| FY2017 | $9.2M | +81.0% |
| FY2016 | $5.1M | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026